The PropThink Weekly Wrap-Up
Most Popular - The FDA will decide on Lymphoseek’s approval in April, a major catalyst for Navidea (NAVB). Interest will again build in the some-what controversial name, and … Continue Reading
Read nowMost Popular - The FDA will decide on Lymphoseek’s approval in April, a major catalyst for Navidea (NAVB). Interest will again build in the some-what controversial name, and … Continue Reading
Read nowLong Ideas - Halozyme Therapeutics (NASDAQ:HALO) will likely continue to move higher Monday after an upgrade from BMO Capital Markets, which has increased its outlook from Neutral to … Continue Reading
Read nowLong Ideas - Shares of ViroPharma (NASDAQ:VPHM) have been pressured in 2012 (falling over 17% as of December 26), as generic competition for one of its drugs has … Continue Reading
Read nowLong Ideas - Happy Holidays from the team at PropThink! Our report on Trius Therapeutics tackled the short thesis, repudiating the focal points of the bear argument. Shares are, … Continue Reading
Read nowLong Ideas - Halozyme Therapeutics (NASDAQ:HALO) announced that it has licensed the use of its technology platform to Pfizer Inc. (NYSE:PFE) to develop Pfizer’s biologics with Halozyme’s Enhanze … Continue Reading
Read nowMost Popular - Abbot Labs recorded the first sale of Amitiza in Japan, resulting in a $15M milestone payment to Sucampo on Tuesday. Nevertheless, the thinly-traded equity reacted … Continue Reading
Read nowLong Ideas - Halozyme Therapeutics (NASDAQ:HALO) announced on Saturday that its partner Roche (OTC: RHHBY) submitted its European application to market subcutaneous (SC) MabThera, also known as Rituxan. … Continue Reading
Read now